Telix Pharmaceuticals to acquire and merge with BlackRock-backed ITM for up to $2.35bn

🇺🇸 PE Hub (US) —
Telix Pharmaceuticals to acquire and merge with BlackRock-backed ITM for up to $2.35bn

AI Summary

Telix Pharmaceuticals announced plans to acquire and merge with BlackRock-backed ITM for up to $2.35 billion. The deal includes $1.65 billion upfront cash payment for 100% of ITM's shares plus up to $700 million in contingent payments, signaling a major consolidation in the pharmaceutical sector.

Telix will pay $1.65 billion in cash upfront for 100 percent of ITM's shares, plus up to $700 million in contingency payments. The post Telix Pharmaceuticals to acquire and merge with BlackRock-backed ITM for up to $2.35bn appeared first on PE Hub.

Markets Deals Health Telix Pharmaceuticals ITM acquisition BlackRock merger pharmaceutical deal contingency payments

Read original source →